Lilian Yan Liang

Lilian Yan Liang

Auto-generated profile, based on publicly available information

Lilian Yan Liang

Medical Data Analytics Centre (MDAC) The Chinese University of Hong Kong Hong Kong SAR China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2022 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
VHVicki Wing‐Ki Hui
Vicki Wing‐Ki Hui
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
LLLilian Yan Liang
Lilian Yan Liang
XZXinrong Zhang
Xinrong Zhang
VWVincent Wai-Sun Wong
Vincent Wai-Sun Wong

7 August 2023 in Gut
Verified
Journal Article
Open access
PDF file
XZXinrong Zhang
Xinrong Zhang
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
WLWei-Xuan Leow
Wei-Xuan Leow
LLLilian Yan Liang
Lilian Yan Liang
VWVincent Wai-Sun Wong
Vincent Wai-Sun Wong
Objective We aimed to test the hypothesis that automated fibrosis score calculation and electronic reminder messages could increase the detection of advanced liver disease in patients with type 2 diabetes. Design In this pragmatic randomised controlled trial at five general medical or diabetes clinics in Hong Kong and Malaysia, we randomly assigned patients in a 1:1 ratio to the intervention group with Fibrosis-4 index and aspartate aminotransferase-to-platelet ratio index automatically calculated based on routine blood tests, followed by electronic reminder messages to alert clinicians of abnormal results, or the control group with usual care. The primary outcome was the proportion of patients with increased fibrosis scores who received appropriate care (referred for hepatology care or specific fibrosis assessment) within 1 year. Results Between May 2020 and Oct 2021, 1379 patients were screened, of whom 533 and 528 were assigned to the intervention and control groups, respectively. A total of 55 out of 165 (33.3%) patients with increased fibrosis scores in the intervention group received appropriate care, compared with 4 of 131 (3.1%) patients in the control group (difference 30.2% (95% CI 22.4% to 38%); p<0.001). Overall, 11 out of 533 (2.1%) patients in the intervention group and 1 out of 528 (0.2%) patients in the control group were confirmed to have advanced liver disease (difference 1.9% (95% CI 0.61% to 3.5%); p=0.006). Conclusion Automated fibrosis score calculation and electronic reminders can increase referral of patients with type 2 diabetes and abnormal fibrosis scores at non-hepatology settings. Trial registration number NCT04241575.

31 August 2023 in Liver International
Verified
Journal Article
Open access
GLGuanlin Li
Guanlin Li
HLHuapeng Lin
Huapeng Lin
PSPimsiri Sripongpun
Pimsiri Sripongpun
LLLilian Y. Liang
Lilian Y. Liang
XZXinrong Zhang
Xinrong Zhang
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
Background & Aims: The steatosis‐associated fibrosis estimator (SAFE) score was developed to detect clinically significant liver fibrosis in patients with NAFLD in the United States. We compare the performance of the SAFE score and other non‐invasive tests to diagnose liver fibrosis and to correlate the scores with liver‐related outcomes in patients with NAFLD in Hong Kong.Methods: This was a retrospective cohort study involving two data sets. The first cohort was a biopsy cohort of NAFLD patients (n = 279), and the second was a territory‐wide cohort of NAFLD patients (n = 4603) retrieved from a territory‐wide electronic healthcare database in Hong Kong.Results: In detecting significant fibrosis, liver stiffness measured by transient elastography had the highest area under the receiver operating characteristic curve (AUROC) (.844), followed by SAFE score (.773). SAFE score had the highest AUROC among blood‐based algorithms (.773 vs. .746 for FIB‐4, .697 for APRI). Based on cut‐off values of SAFE score (0 and 100 points), 854 (18.6%), 1596 (34.6%) and 2153 (46.8%) were in the low‐, intermediate‐ and high‐risk groups, respectively, in the territory‐wide cohort. Six (.7%), 15 (.9%) and 59 (2.7%) developed liver‐related events in those three groups respectively. Among patients who had liver‐related events at 5 years, using the high cut‐off, SAFE score could predict 84.9% of patients accurately, compared to 40.9% for FIB‐4 and 27.2% for APRI.Conclusion: The SAFE score performed well and better than other blood‐based markers in diagnosing significant fibrosis and predicting liver‐related events in Asian patients with NAFLD.

30 August 2023 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
HLHuapeng Lin
Huapeng Lin
JLJimmy Che‐To Lai
Jimmy Che‐To Lai
GWGrace Lai‐Hung Wong
Grace Lai‐Hung Wong
ADAdèle Delamarre
Adèle Delamarre
SASang Hoon Ahn
Sang Hoon Ahn
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
Summary: Background: Baveno VII was proposed for non‐invasive identification of clinically significant portal hypertension. However, a substantial proportion of patients is classified in the grey zone (i.e., liver stiffness 15–24.9 kPa and/or platelet count <150 × 109/L).Aims: To evaluate the risk and predictors of hepatic decompensation in patients in the grey zone, and to determine the prognostic role of spleen stiffness measurement.Methods: We included prospective cohorts (from Hong Kong, Korea and France) of patients who had undergone transient elastography examination for chronic liver disease. We estimated risk of hepatic decompensation using competing risk regression with hepatocellular carcinoma and non‐liver‐related death as competing events.Results: We identified 2763 patients with compensated advanced chronic liver disease (cACLD). There were 1243 (44.9%) and 536 (19.4%) patients in the Baveno VII grey zone and high‐risk groups, respectively. The cumulative incidence of decompensation at 5 years was significantly different among low‐risk (0.6% [95% CI: 0.2%–1.3%]), grey zone 4.2% (95% CI: 3.1%–5.4%) and high‐risk groups (11.4% [95% CI: 8.7%–14.6%]). By competing risk analysis, aetiology of liver disease (alcohol‐related liver disease), albumin–bilirubin score and alkaline phosphatase level were independently associated with decompensation among patients in the grey zone. The combination of Baveno VII and spleen stiffness significantly reduced patients classified into grey zone (12.8% in cACLD patients), while maintaining high discrimination of decompensation in low‐ and high‐risk groups.Conclusions: Patients in grey zone of Baveno VII criteria remain at high risk of hepatic decompensation. Clinical risk factors and spleen stiffness can further stratify the risk in such patients.

14 February 2024 in Liver International
Verified
Journal Article
Open access
SSSherlot J. Song
Sherlot J. Song
ANAsako Nogami
Asako Nogami
LLLilian Y. Liang
Lilian Y. Liang
MYMasato Yoneda
Masato Yoneda
HLHoward H.W. Leung
Howard H.W. Leung
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
Background & Aims: FibroScan® Expert 630 and FibroScan® Mini+430 are novel vibration‐controlled transient elastography devices equipped with the same SmartExam software, which allows continuous measurement of controlled attenuation parameter (CAP) during the entire examination. This study aims to compare the CAP variabilities and the quantification for liver fibrosis and steatosis between the conventional FibroScan and the SmartExam‐equipped machines in patients with metabolic dysfunction‐associated steatotic liver disease (MASLD).Methods: This retrospective study included 118 patients with biopsy‐proven MASLD who underwent liver biopsy at two tertiary centres between 2021 and 2023. Liver stiffness and steatosis measurements were performed using both FibroScan machines and M and XL probes for each individual. Liver histology was used as the reference standard for liver fibrosis and steatosis staging.Results: Standard deviations of continuous CAP (cCAP) were significantly lower than those of CAP for all probes (p < .0001). CAP variability was significantly associated with body mass index (p < .01), probe selection (p < .001) as well as the random effect of centre. Only the effect of probe selection (p < .001) was significantly associated with cCAP variability. No significant difference was found in the performance of staging liver fibrosis and steatosis between two types of machines at the same cut‐offs.Conclusions: The SmartExam‐based VCTE reduces the variability of CAP measurement and achieves a similar accuracy as the FibroScan 502 device for the estimation of both hepatic steatosis and fibrosis. Future studies should determine if cCAP is a better tool to monitor changes in steatosis than the original CAP.

25 May 2022 in Journal of Medical Virology
Verified
Journal Article
Closed access
LLLilian Yan Liang
Lilian Yan Liang
Terry Cheuk-Fung YipTerry Cheuk-Fung Yip
Terry Cheuk-Fung Yip
JLJimmy Che‐To Lai
Jimmy Che‐To Lai
ALAmy Shuk‐Man Lam
Amy Shuk‐Man Lam
YTYee‐Kit Tse
Yee‐Kit Tse
GWGrace Lai‐Hung Wong
Grace Lai‐Hung Wong